Diverse Parties Say Federal Biotech Rules Confusing
by Pat Rizzuto (BNA) The federal approach to regulating bioengineered products is a confusing labyrinth, according to companies, trade associations, advocacy groups and scientists. Companies must follow a maze to identify which agencies may have jurisdiction over a bioengineered product and